GlassScriptPhysician profile
Michael J Naughton
NPI 1295752830
$248,750.51
in general payments reported to CMS, 2019-2025
50 companies · $47K in 2025
The $47K reported for 2025 was more than what 95% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $21K · 2021: $4,035 · 2022: $24K · 2023: $29K · 2024: $34K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Consulting Fee: $21K · Travel and Lodging: $6,067 · Food and Beverage: $5,121 · Education: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,105.00 |
| Consulting Fee | $21,395.00 |
| Travel and Lodging | $6,067.01 |
| Food and Beverage | $5,121.30 |
| Education | $494.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $89,710.32 | 2019-2025 | Enhertu, Datroway, Imfinzi |
| Celgene Corporation | $50,559.13 | 2019-2025 | Reblozyl |
| Eisai INC. | $41,134.73 | 2019-2025 | |
| Daiichi Sankyo INC. | $27,660.50 | 2019-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $25,667.05 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $3,976.06 | 2019-2025 | Imdelltra (Amg757), Lumakras |
| Sirtex Medical INC | $3,492.18 | 2019 | |
| Gilead Sciences, INC. | $1,176.04 | 2021-2025 | Trodelvy |
| Seagen INC. | $678.60 | 2020-2023 | Tukysa, Padcev |
| Janssen Biotech, INC. | $673.19 | 2019-2025 | Rybrevant, Carvykti |
| Emd Serono, INC. | $474.32 | 2023-2025 | Bavencio |
| Incyte Corporation | $471.79 | 2021-2025 | Monjuvi, Jakafi, Jakafi |
| Pfizer INC. | $368.40 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $360.47 | 2020-2024 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Naughton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.